|Dr. James A. Helliwell||CEO & Director||N/A||N/A||1974|
|Mr. Bruce G. Cousins CPA, C.A., CPA||Pres & CFO||N/A||N/A||1961|
|Dr. Amanda Malone Ph.D.||Chief Scientific Officer||N/A||N/A||1981|
|Mr. Alexander John Rothwell Eng., M.B.A.||Advisor||N/A||N/A||1969|
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Eupraxia Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.